Compare Enveric Biosciences Inc (ENVB) vs Illinois Tool Works Inc. (ITW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Illinois Tool Works Inc. — how do they compare? Enveric Biosciences Inc trades at $1.45 (market cap $6.20M), while Illinois Tool Works Inc. trades at $293.28 (market cap $83.88B). The key difference: Illinois Tool Works Inc. is far larger — about 13529× Enveric Biosciences Inc's market cap, and Illinois Tool Works Inc. pays a 2.34% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | ITW | |
|---|---|---|
Market Cap | $6.20M | $83.88B |
Sector | Health | Industrials |
52-Week High | $17.40 | $299.60 |
52-Week Low | $1.27 | $241.07 |
Enterprise Value | $1.30M | $92.73B |
Dividend Yield | — | 2.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.55, down 0.64% with a bullish technical signal despite negative profitability. The company shows promising clinical progress with its lead candidate EB-003, supported by recent FDA guidance and positive preclinical data. While quarterly earnings consistently beat expectations, the company remains unprofitable with negative ROE and ROA. Analyst sentiment is positive with 75% buy ratings.
Investment outlook hinges on successful drug development milestones, with regulatory progress and intellectual property expansion providing catalysts. Key risks include clinical trial outcomes, cash burn from operations, and dependence on financing activities. The stock presents speculative growth potential for risk-tolerant investors focused on biotech innovation.
ITW trades at $296.66, up 0.67% with a bullish technical outlook and strong support at $292. The company maintains robust profitability with 19.39% net margins and has beaten earnings estimates for three consecutive quarters. Recent positive developments include a 7% dividend increase and $6 billion share repurchase authorization announced August 7, 2026.
While valuation metrics appear elevated (P/E 26.87, P/B 29.19), ITW's consistent earnings performance and shareholder-friendly actions support upside to the $316 consensus target. Key risks include construction sector exposure and currency headwinds, but operational strength and margin discipline provide stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Illinois Tool Works Inc.
Illinois Tool Works is a diversified global manufacturer that produces specialized industrial equipment, consumables, and related services. The firm operates 87 global divisions through seven distinct operating segments: automotive OEM, construction products, food equipment, specialty products, test/measurement and electronics, polymers and fluids, and welding. About half of its revenue comes from its operations in North America, with the remainder originating from international markets. ITW takes a bottom-up and decentralized approach to portfolio management, with the exception that each segment must apply its 80/20 operating process modeled on the Pareto principle.
Read more on ITW →
